A peer-reviewed study analyzing more than one million children found that rare cases of Myocarditis and Pericarditis were observed within vaccinated groups, according to research published in the journal Epidemiology.

The study, conducted by researchers from the University of Oxford, University of Bristol, and Harvard T.H. Chan School of Public Health, examined the safety and effectiveness of the Pfizer-BioNTech COVID-19 Vaccine in children ages 5 to 15.

Using health data from England, researchers compared hundreds of thousands of vaccinated children with matched unvaccinated peers. They found that vaccination provided an initial protective effect against COVID-19 and was associated with fewer emergency room visits, though that protection declined after several weeks.

At the same time, the study documented myocarditis and pericarditis cases only in the vaccinated groups within this dataset, with rates estimated at 27 and 10 cases per million following the first and second doses, respectively. Researchers cautioned that the absence of such cases in the unvaccinated group in this analysis does not mean the conditions cannot occur independently of vaccination.

The findings align with prior reporting from the UK Health Security Agency, which has identified heart inflammation as a rare side effect, particularly among younger populations.

Importantly, researchers noted a key distinction by age group. Among adolescents, the reduction in risk of COVID-19 hospitalization following vaccination was greater than the increased risk of these rare heart conditions. For younger children, however, the balance of risk and benefit appeared smaller.

The study adds to ongoing debate over pediatric COVID-19 vaccination policy. Rand Paul has pointed to such findings in advocating for legislation to remove liability protections for vaccine manufacturers, arguing families should have more legal recourse.

Health authorities, including the U.S. Food and Drug Administration, have acknowledged rare risks associated with the vaccines and have required updated labeling to reflect potential cardiac side effects, while continuing to evaluate safety data.

Researchers emphasized that their findings should be interpreted within the broader clinical context, including both the risks posed by COVID-19 infection itself and the overall rarity of vaccine-associated complications.